{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:07:24Z","timestamp":1761491244246,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T00:00:00Z","timestamp":1622592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T00:00:00Z","timestamp":1622592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Immunogenicity related to treatment with TNF inhibitors (TNFi) is one of the causes for the decreased attainment of clinical response in patients with rheumatoid arthritis (RA). The B-cell activating factor (BAFF) may be playing a role in the development of immunogenicity. The objective of this study was to analyse the association of baseline concentration of serum B-cell activating factor (BAFF) with immunogenicity after 6\u00a0months of TNFi treatment. A total of 127 patients with RA starting a TNFi (infliximab, adalimumab, certolizumab pegol or golimumab) were followed-up for 6\u00a0months. Serum samples were obtained at baseline and at 6\u00a0months and anti-drug antibody (ADA) and BAFF concentrations were measured. Logistic regression models were employed in order to analyse the association between BAFF concentrations and immunogenicity. Receiver operating characteristic analysis was performed to determine the BAFF concentrations with a greater likelihood of showing immunogenicity association. At 6\u00a0months, 31 patients (24%) developed ADA. A significant interaction between the age and baseline BAFF concentration was found for the development of ADA (Wald chi-square value\u2009=\u20095.30; p\u2009=\u20090.02); therefore, subsequent results were stratified according to mean age (\u2264\u2009\/\u2009&gt;\u200955\u00a0years). Baseline serum BAFF concentration was independently associated with ADA development only in patients over 55\u00a0years (OR\u2009=\u20091.51; 95% CI 1.03\u20132.21). Baseline serum BAFF\u2009\u2265\u20091034\u00a0pg\/mL predicted the presence of ADA at 6\u00a0months (AUC\u2009=\u20090.81; 95% confidence interval (CI) 0.69\u20130.93; p\u2009=\u20090.001; positive likelihood ratio\u2009=\u20093.7). In conclusion, our results suggest that the association of BAFF concentration and immunogenicity depends on the patient\u2019s age. Baseline serum BAFF concentration predicts the presence of ADA within 6\u00a0months of TNFi therapy in older patients with RA.<\/jats:p>","DOI":"10.1038\/s41598-021-91177-4","type":"journal-article","created":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T10:08:04Z","timestamp":1622628484000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2630-3312","authenticated-orcid":false,"given":"Borja","family":"Hern\u00e1ndez-Breijo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Navarro-Comp\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chamaida","family":"Plasencia-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Parodis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna E.","family":"Gehin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Mart\u00ednez-Feito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Novella-Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Araceli","family":"Mezcua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Nozal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dora","family":"Pascual-Salcedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Balsa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,2]]},"reference":[{"key":"91177_CR1","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1093\/rheumatology\/ker124","volume":"50","author":"D Pascual-Salcedo","year":"2011","unstructured":"Pascual-Salcedo, D. et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford) 50, 1445\u20131520 (2011).","journal-title":"Rheumatology (Oxford)"},{"key":"91177_CR2","doi-asserted-by":"publisher","first-page":"497","DOI":"10.4049\/jimmunol.1102321","volume":"188","author":"M Kreuzaler","year":"2012","unstructured":"Kreuzaler, M. et al. Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors. J. Immunol. 188, 497\u2013503 (2012).","journal-title":"J. Immunol."},{"key":"91177_CR3","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1002\/art.38736","volume":"66","author":"S Glaesener","year":"2014","unstructured":"Glaesener, S. et al. Distinct effects of methotrexate and etanercept on the B cell compartment in patients with juvenile idiopathic arthritis. Arthritis Rheumatol. 66, 2590\u20132600 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"91177_CR4","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1136\/annrheumdis-2018-213403","volume":"77","author":"S Bitoun","year":"2018","unstructured":"Bitoun, S. et al. Methotrexate and BAFF interaction prevents immunization against TNF inhibitors. Ann. Rheum. Dis. 77, 1463\u20131470 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"91177_CR5","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1093\/rheumatology\/kex474","volume":"57","author":"A Balsa","year":"2018","unstructured":"Balsa, A. et al. Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: The REASON study. Rheumatology (Oxford) 57, 688\u2013693 (2018).","journal-title":"Rheumatology (Oxford)"},{"key":"91177_CR6","doi-asserted-by":"publisher","first-page":"e13057","DOI":"10.14814\/phy2.13057","volume":"4","author":"MC Morissette","year":"2016","unstructured":"Morissette, M. C. et al. Role of BAFF in pulmonary autoantibody responses induced by chronic cigarette smoke exposure in mice. Physiol. Rep. 4, e13057 (2016).","journal-title":"Physiol. Rep."},{"key":"91177_CR7","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.smim.2006.06.002","volume":"18","author":"SL Kalled","year":"2006","unstructured":"Kalled, S. L. Impact of the BAFF\/BR3 axis on B cell survival, germinal center maintenance and antibody production. Semin. Immunol. 18, 290\u2013296 (2006).","journal-title":"Semin. Immunol."},{"key":"91177_CR8","first-page":"1256","volume":"35","author":"S Bosello","year":"2008","unstructured":"Bosello, S. et al. Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis. J. Rheumatol. 35, 1256\u20131264 (2008).","journal-title":"J. Rheumatol."},{"key":"91177_CR9","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/1529-0131(200106)44:6<1313::AID-ART223>3.0.CO;2-S","volume":"44","author":"GS Cheema","year":"2001","unstructured":"Cheema, G. S., Roschke, V., Hilbert, D. M. & Stohl, W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 44, 1313\u20131319 (2001).","journal-title":"Arthritis Rheum."},{"key":"91177_CR10","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/imr.12810","volume":"292","author":"SW Jackson","year":"2019","unstructured":"Jackson, S. W. & Davidson, A. BAFF inhibition in SLE-Is tolerance restored?. Immunol. Rev. 292, 102\u2013119 (2019).","journal-title":"Immunol. Rev."},{"key":"91177_CR11","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/ar1180","volume":"6","author":"SA Johnson","year":"2004","unstructured":"Johnson, S. A. & Cambier, J. C. Ageing, autoimmunity and arthritis: Senescence of the B cell compartment\u2014implications for humoral immunity. Arthritis Res. Ther. 6, 131\u2013139 (2004).","journal-title":"Arthritis Res. Ther."},{"key":"91177_CR12","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2011.406","volume":"305","author":"GM Bartelds","year":"2011","unstructured":"Bartelds, G. M. et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 305, 1460\u20131468 (2011).","journal-title":"JAMA"},{"key":"91177_CR13","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/BOR.0b013e3283521c4e","volume":"24","author":"C Krieckaert","year":"2012","unstructured":"Krieckaert, C., Rispens, T. & Wolbink, G. Immunogenicity of biological therapeutics: From assay to patient. Curr. Opin. Rheumatol. 24, 306\u2013311 (2012).","journal-title":"Curr. Opin. Rheumatol."},{"key":"91177_CR14","doi-asserted-by":"publisher","first-page":"3782","DOI":"10.1002\/art.22214","volume":"54","author":"K Bendtzen","year":"2006","unstructured":"Bendtzen, K. et al. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum. 54, 3782\u20133789 (2006).","journal-title":"Arthritis Rheum."},{"key":"91177_CR15","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nri2508","volume":"9","author":"CA Siegrist","year":"2009","unstructured":"Siegrist, C. A. & Aspinall, R. B-cell responses to vaccination at the extremes of age. Nat. Rev. Immunol. 9, 185\u2013194 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"91177_CR16","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1016\/j.jaci.2018.02.017","volume":"141","author":"E Blanco","year":"2018","unstructured":"Blanco, E. et al. Age-associated distribution of normal B-cell and plasma cell subsets in peripheral blood. J. Allergy Clin. Immunol. 141, 2208-2219.e16 (2018).","journal-title":"J. Allergy Clin. Immunol."},{"key":"91177_CR17","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1182\/blood-2011-01-330530","volume":"118","author":"Y Hao","year":"2011","unstructured":"Hao, Y., O\u2019Neill, P., Naradikian, M. S., Scholz, J. L. & Cancro, M. P. A B-cell subset uniquely responsive to innate stimuli accumulates in aged mice. Blood 118, 1294\u20131304 (2011).","journal-title":"Blood"},{"key":"91177_CR18","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1006\/clim.2000.4894","volume":"96","author":"E Bandr\u00e9s","year":"2000","unstructured":"Bandr\u00e9s, E. et al. The increase of IFN-gamma production through aging correlates with the expanded CD8(+high)CD28(-)CD57(+) subpopulation. Clin. Immunol. 96, 230\u2013235 (2000).","journal-title":"Clin. Immunol."},{"key":"91177_CR19","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1182\/blood.V97.1.198","volume":"97","author":"B Nardelli","year":"2001","unstructured":"Nardelli, B. et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 97, 198\u2013204 (2001).","journal-title":"Blood"},{"key":"91177_CR20","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1093\/rheumatology\/keu249","volume":"53","author":"P L\u00f3pez","year":"2014","unstructured":"L\u00f3pez, P. et al. Interferon-\u03b1-induced B-lymphocyte stimulator expression and mobilization in healthy and systemic lupus erthymatosus monocytes. Rheumatology (Oxford) 53, 2249\u20132258 (2014).","journal-title":"Rheumatology (Oxford)"},{"key":"91177_CR21","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/apt.15312","volume":"50","author":"S Paul","year":"2019","unstructured":"Paul, S. & Roblin, X. Letter: Immunogenicity of anti-TNF in elderly IBD patients. Aliment Pharmacol. Ther. 50, 336 (2019).","journal-title":"Aliment Pharmacol. Ther."},{"key":"91177_CR22","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1097\/FTD.0000000000000421","volume":"39","author":"F Medina","year":"2017","unstructured":"Medina, F. et al. Current practice for therapeutic drug monitoring of biopharmaceuticals in rheumatoid arthritis. Ther. Drug Monit. 39, 364\u2013369 (2017).","journal-title":"Ther. Drug Monit."},{"key":"91177_CR23","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1136\/annrheumdis-2011-200828","volume":"71","author":"C Plasencia","year":"2012","unstructured":"Plasencia, C. et al. Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab. Ann. Rheum. Dis. 71, 1955\u20131960 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"91177_CR24","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s10067-018-4355-0","volume":"38","author":"A Mart\u00ednez-Feito","year":"2019","unstructured":"Mart\u00ednez-Feito, A. et al. The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors. Clin. Rheumatol. 38, 949\u2013954 (2019).","journal-title":"Clin. Rheumatol."},{"key":"91177_CR25","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1136\/annrheumdis-2013-204769","volume":"74","author":"GR Burmester","year":"2015","unstructured":"Burmester, G. R. et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: The randomised CONCERTO trial. Ann. Rheum Dis. 74, 1037\u20131044 (2015).","journal-title":"Ann. Rheum Dis."},{"key":"91177_CR26","first-page":"37","volume":"52","author":"AA Mahdy","year":"2014","unstructured":"Mahdy, A. A., Raafat, H. A., El-Fishawy, H. S. & Gheita, T. A. Therapeutic potential of hydroxychloroquine on serum B-cell activating factor belonging to the tumor necrosis factor family (BAFF) in rheumatoid arthritis patients. Bull. Fac. Pharm. Cairo Univ. 52, 37\u201343 (2014).","journal-title":"Bull. Fac. Pharm. Cairo Univ."},{"key":"91177_CR27","doi-asserted-by":"publisher","first-page":"102372","DOI":"10.1016\/j.autrev.2019.102372","volume":"18","author":"B Hern\u00e1ndez-Breijo","year":"2019","unstructured":"Hern\u00e1ndez-Breijo, B., Gomez, A., Soukka, S., Johansson, P. & Parodis, I. Antimalarial agents diminish while methotrexate, azathioprine and mycophenolic acid increase BAFF levels in systemic lupus erythematosus. Autoimmun. Rev. 18, 102372 (2019).","journal-title":"Autoimmun. Rev."},{"key":"91177_CR28","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s13075-019-2009-5","volume":"21","author":"JE Gehin","year":"2019","unstructured":"Gehin, J. E. et al. Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: Data from the NOR-DMARD study. Arthritis Res. Ther. 21, 256 (2019).","journal-title":"Arthritis Res. Ther."},{"key":"91177_CR29","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha, D. et al. 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 62, 2569\u20132581 (2010).","journal-title":"Arthritis Rheum."},{"key":"91177_CR30","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.reuma.2015.05.001","volume":"11","author":"R Sanmart\u00ed","year":"2015","unstructured":"Sanmart\u00ed, R. et al. 2014 update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritis. Reumatol. Clin. 11, 279\u2013294 (2015).","journal-title":"Reumatol. Clin."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91177-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91177-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91177-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T09:13:08Z","timestamp":1670058788000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91177-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,2]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["91177"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-91177-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2021,6,2]]},"assertion":[{"value":"20 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"V.N-C reports speaker fees and grants from Abbvie, Janssen, Lilly, MSD, Novartis, Pfizer and UCB during the conduct of the study. CP-R has received research grants\/honoraria from AbbVie, Lilly, Novartis, Pfizer, Sanofi, Biogen and UCB. I.P. has received research funding from GlaxoSmithKline and Elli Lilly and Company, and honoraria from Gilead Sciences, GlaxoSmithKline and Novartis; all of the above are unrelated to this work. JE.G reports speaker fees from Roche. D.P-S reports speaker fees and grants from Abbvie, Grifols, Menarini, Novartis, Pfizer and Takeda during the conduct of the study. A.B reports grants, consultancies and speaker fees from Abbvie, BMS, Nordic, Novartis, Pfizer, Sandoz, Sanofi, Roche and UCB during the conduct of the study. The other authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11632"}}